Extends ALS research and therapy funding through 2031

Congress file s4472-119, before Congress. Still to be decided as of 2026-08-04.

Latest action: Passed Senate with an amendment by Voice Vote. (consideration: CR S4425-4426; text: CR S4425-4426)

What it does

ALS patients get longer access to experimental drugs The law extends through 2031 programs that let ALS patients try investigational drugs outside formal clinical trials, and requires better safety reporting from researchers running these programs.

The bigger picture

Drug makers and researchers get clearer FDA guidance The FDA must publish and update action plans every five years on how it will support neurodegenerative disease drug development, including what barriers exist and what resources they need.

What to watch

Eligibility rules remain unchanged for trial access The law extends current programs but does not change which patients qualify for expanded access grants or lower the barriers to entry for patients excluded from traditional clinical trials.

Official summary

This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases.The bill reauthorizesgrants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials,grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, anda Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the bill revises the NIH grants to require (1) the NIH, in considering grant renewal, to assess available information on the safety and efficacy of the investigational drugs; (2) grantees to promptly report available safety data from ongoing clinical trials; and (3) the NIH to determine the timeframe for enrollment in clinical trials for the investigational drugs.Additionally, every five years, the FDA must publish a plan describ

Read the official record for s4472-119

See everything up for a vote · This week in Congress · See what we have filed with the clerk